Castuner
Engadir un podcast

Escóitao na túa aplicación

Episodios

422 episodios

  1. The Treatment Planning Process for Atopic Dermatitis 1:43
  2. A Multidisciplinary Approach to Treating Itch 0:49
  3. Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs 5:30
  4. Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex 8:45
  5. Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load 8:45
  6. The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion 5:45
  7. Potassium Binders to Optimize GDMT Therapy in HFrEF 6:45
  8. CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia 9:00
  9. From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection 5:15
  10. The Binder Selection Playbook: Matching the Right Strategy to the Right Patient 17:15
  11. Mechanism of Action for Aryl Hydrocarbon Receptor Agonists 7:00
  12. Tapinarof’s Place in Inflammatory Disease Treatment 4:59
  13. Skin Barrier Maintenance in Atopic Dermatitis and Psoriasis 4:01
  14. Various Benefits of Aryl Hydrocarbon Receptor Agonists 9:19
  15. Managing Patient Expectations with Topical Therapies 5:32
  16. Potential Impact of Aryl Hydrocarbon Activation on Pigment 5:03
  17. The Hidden Danger of IgAN: Pathogenesis and Unmet Needs 6:00
  18. Unmasking IgAN: Achieving Earlier Diagnosis 6:45
  19. Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal 6:30
  20. Navigating KDIGO Guidance in IgAN 4:15
  21. Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN 4:30
  22. Translating Evidence into IgAN Care 8:45
  23. The Evolving Role of Biomarkers in IgAN 4:45
  24. The Future of IgAN Care 5:30
  25. Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders 5:15
  26. Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression 6:00
  27. The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape 7:30
  28. Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens 3:45
  29. Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy 9:00
  30. Treating Outside the Box: New Pathways to Retinal Vascular Stability 44:00
  31. Ready, Set, Act! Opportunities to Address Persistent Unmet Needs in Patients With HFrEF: A Case-Based Discussion 16:00
  32. Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma 5:30
  33. Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients 9:15
  34. Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma 5:15
  35. Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients 9:45
  36. Hypoparathyroidism – The Critical Role of Genetics in Your Differential Diagnosis 45:00
  37. Mineralocorticoid Receptor Antagonists in Heart Failure: The Evolving Treatment Landscape 55:00
  38. Overcoming Challenges in Transthyretin Cardiac Amyloidosis 58:45
  39. Frontline Champions: Nurses as Drivers of Symptom-Based CKD-aP Care 7:30
  40. CKD-aP Uncovered Prevalence & Pathophysiology 5:15
  41. When Itching Hurts: Quality of Life Disruption in CKD-aP 5:30
  42. Gabapentinoids: Safety Considerations and Downstream Outcomes 4:15
  43. From Scratch to Strategy: Talking About CKD-aP in Clinical Practice 5:00
  44. Spotlight on Assessment: Tools That Capture CKD-aP 7:30
  45. Reading Between the Lines: What PROMs Reveal About Itch 3:45
  46. What You Don’t See: A Patient’s View of Living with CKD-aP 6:00
  47. Winning the CKD-aP Battle: A United Physician-Nurse Front 5:00
  48. Conference Coverage at ICCBH 2026: From Achondroplasia Presentation to Practice 16:30
  49. Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice 32:30
  50. Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer 11:30